Publicaciones Científicas

Valadez, G. V., Sutter, G., Garcia Carranca., Jose, Marco-V., Erfle, V., Norma, G., Merchant, H, and Rosales, R*. (2000).The highly attenuatted MVA strain of vaccinia virus carrying the E2 gene of bovine papillomavirus is able to stop growth of human tumors generated in nude mice. Cancer. 88 (7): 1650-1662. FI. 3.94

Rosales, C., Valadez-Graham V., Arrellin, G., Merchant, H., and  Rosales R*. (2000). 
MVA E2 a Recombinant  Vaccinia Containing the papilloma Virus E2 Protein Promotes Tumor Regression By Stimulating Macrophage Antibody-Dependent Cytotoxicity. Cancer Immunology Immunotherapy. 49 (7):347-360. FI. 2.75

Ricardo Rosales*., Mario López-Contreras and Roberto Risco. (2001). Antibodies against the human papillomavirus (HPV) 16and 18 E2, E6 and E7 proteins in Sera:  Correlation with the presence of papillomavirus DNA. Journal of Medical Virology.  65:736-744. FI. 2.62

Erick García-García, Ricardo Rosales and Carlos Rosales*. (2002). Phosphatidylinositol 3-Kinase and Extracellular signal-regulated kinase recruited for Fc receptor-medisted phagocytosis during manocyte to macrophage differentiation. Journal of Leukocyte Biology.Vol 72: 108-113. FI. 4.13

Corona- Gutierres, Manuel..et al.. Rosales Ricardo*. (2002). A Phase II Study: Efficacy of the Gene Therapy of the MVA E2 Recombinant Virus in the Treatment of Precancerous Lesions (NIC I and NIC II) Associated with Infection of Oncogenic Human Papillomavirus.Human Gene Therapy.  13:1127-1140. FI. 4.96


Rincón_Arano, H., Rosales, R., Mora, N., Rodríguez-Castañeda, A., Rosales, C*. (2003).
R-Ras promotes Tumor Growth of Cervix Ephithelial Cells.Cancer. Vol (97). No.3: 575-585  FI. 3.9

José Luis Roque-Reséndiz, Ricardo Rosales* and Pascal Herion (2004)MVA ROP2 Vaccinia Virus Recombinant as a Vaccine Candidate for ToxoplasmosisParasitology. 128, 397-405. FI 1.82.

Carlos Manuel Corona Gutierrez, Alberto Tinoco, Tania Navarro,  Mario López Contreras, Roberto  Risco Cortes, Patricia Calzado, Lise Reyes, Roberto Posternak, Gianni Morosoli, Mauro Lara Verde, Ricardo Rosales (2004). Therapeutic Vaccination with MVA E2 is able to Eliminate Precancerous Lesions (CIN I, CIN II and CIN III) Associated with Infection of Oncogenic Human Papillomavirus.Human Gene Therapy. 15(5): 421-431. FI 4.96

García-Hernández, E.,  González-Sánchez, JL., Andrade-Manzano, A.,  L Contreras, M., Padilla, S., Guzmán, C., Jiménez, R., Reyes, L., Morosoli, G., Verde, ML., and Rosales R (2006). Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine.Cancer Gene Therapy. 13: 592-597.

Albarran y Carvajal, A.,  de la Garza, A., Cecilio Cruz Quiroz, BJ., Vazquez Zea E.,  Díaz Estrada, I.,  Mendez Fuentez, E.,  López Contreras, M., Andrade-Manzano, A.,  Santiago Padilla,  and  Rosales R. (2007).  A Phase I/II Study: MVA E2 Recombinant Vaccine in The treatment of papillomavirus infection in men presenting intraurethral FLAT condyloma. BioDrugs. 21 (1): 47-50.

Mora, N., Rosales, R., and Rosales C. (2007). R-Ras promotes metastasis of cervical cancer epithelial cells. Cancer Immunology Immunotherapy. 56: 535-544

Mata-Espinosa DA*‚Ć, Mendoza-Rodríguez V‚Ć, Aguilar-León D*, Rosales R‚ƂƬ∂, López-Casillas F‚Ć and Hernández-Pando R* (2008). Gene Therapy with Adenovirus-interferon-g recombinant virus in progressive pulmonary tuberculosis using a murine model. Molecular Therapy. Vol 16 (6): 1065-1072